US-based Sagent Pharmaceuticals (SGNT) has introduced an antineoplastic agent 'Carboplatin Injection' in four preservative-free vial presentations.
The injection is indicated for the initial treatment of advanced ovarian carcinoma in combination with other approved chemotherapeutic agents as well as for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.
Along with all other products in the company's portfolio, Carboplatin features Sagent's PreventIV Measures packaging and labeling, which is designed to help reduce medication errors.
The company said Carboplatin is the first product manufactured at its 300,000ft2 FDA and cGMP compliant sterile SCP manufacturing facility located in Chengdu, China that uses isolator technology.
SCP facility was designed initially to support the supply of chronically short oncology products.
Sagent is focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.
